Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced MelanomaCaroline Robert, Victoria Atkinson, Anna Maria Di Giacomo et al.|Journal of Clinical Oncology|2020Cited by 226
74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMAJennifer L. Crombie, Juan Pablo Alderuccio, Robert Redd et al.|Hematological Oncology|2025Cited by 3